Efficacy and Safety of Luspatercept in Patients with HbE/β-Thalassemia from the BELIEVE Study: A Subgroup Analysis
Kevin H.M. Kuo(University Health Network), Vip Viprakasit(Siriraj Hospital), Pranee Sutcharitchan(Chulalongkorn University), Ai Sim Goh(Hospital Pulau Pinang), Yinzhi Lai(Bristol-Myers Squibb (United States)), Lee Ping Chew, Thomas D. Coates(Children's Hospital of Los Angeles), Wen‐Ling Kuo(Chang Gung University), Ping Chong Bee(University Malaya Medical Centre), Loyse Felber Medlin(Bristol-Myers Squibb (Switzerland)), Soo Min Lim(Sultanah Aminah Hospital), Luciana Moro Bueno(Bristol-Myers Squibb (Switzerland)), Martina Perin(Bristol-Myers Squibb (Switzerland)), Sadanand Vodala(Bristol-Myers Squibb (United States))
Cited by 1
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical Classification, Screening and Diagnosis for Thalassemia
|Hematology/Oncology Clinics of North America|2018|262
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162